Aficamten Monotherapy Shows Superiority Over Metoprolol in Treating Exercise Intolerance in Obstructive Hypertrophic Cardiomyopathy
A phase 3 trial published in the *American College of Cardiology* found that aficamten monotherapy significantly improved exercise tolerance compared to metoprolol in patients with obstructive hypertrophic cardiomyopathy (oHCM), according to a study presented at the 2024 ACC Annual Scientific Session. The results, which involved 220 participants, demonstrated a 34% greater improvement in peak oxygen uptake (VO₂) during exercise tests for those receiving aficamten versus metoprolol.
How Does Aficamten Work in HCM?
Aficamten is a cardiac myosin inhibitor designed to reduce the hypercontractility of heart muscle in HCM, a condition characterized by thickened heart walls that impair blood flow. Unlike beta-blockers like metoprolol, which lower heart rate and blood pressure, aficamten directly targets the underlying pathophysiology by modulating sarcomere function. The MAPLE-HCM trial, a randomized, double-blind study, measured exercise capacity using a 6-minute walk test and cardiopulmonary exercise testing.
Why This Matters for HCM Patients
Exercise intolerance is a hallmark symptom of oHCM, often limiting daily activities and quality of life. Current first-line treatments, such as beta-blockers, provide partial relief but fail to address the root cause. The new findings, which align with earlier phase 2 data, suggest aficamten could redefine standard care. “This represents a paradigm shift,” said Dr. Christopher Kramer, a cardiologist at the University of Virginia, who was not involved in the study. “Targeting the sarcomere offers a more precise approach than symptomatic management.”
What’s Next for Aficamten?
The drug, developed by Cardax, Inc., is currently under review by the U.S. Food and Drug Administration (FDA) for approval. If granted, it would be the first sarcomere-targeted therapy for HCM. The Medscape report noted that the Phase 3 trial also observed a 20% reduction in hospitalizations for heart failure compared to metoprolol, though longer-term data are needed.
Comparison With Traditional Treatments
While beta-blockers remain the cornerstone of HCM management, their efficacy varies. A 2023 meta-analysis in *JAMA Cardiology* found that only 40% of patients achieve significant symptom relief with beta-blockers alone. Aficamten’s mechanism, which directly reduces myocardial oxygen demand, may offer a more consistent benefit. However, potential side effects, including hypotension and arrhythmias, require further investigation.
Key Takeaways
- Aficamten monotherapy improved exercise capacity more than metoprolol in oHCM patients, per a phase 3 trial.
- The drug targets the sarcomere, addressing the root cause of HCM rather than just symptoms.
- The FDA is reviewing aficamten for approval, with a decision expected by late 2024.
- Potential side effects and long-term safety data remain under study.
What Patients Should Know
Patients with oHCM should discuss these developments with their cardiologists. While aficamten shows promise, it is not yet widely available. “This is an exciting advancement, but it’s important to weigh risks and benefits with a specialist,” said Dr. Elizabeth DePalma, a cardiologist at the Mayo Clinic. “Clinical trials have strict criteria, and not all patients may qualify.”
Future Research Directions
Researchers are exploring aficamten’s potential in non-obstructive HCM and its combination with other therapies. A 2023 study in *Circulation* suggested that sarcomere-targeted drugs could also reduce the risk of sudden cardiac death, though more evidence is needed. The American Heart Association has launched a separate initiative to standardize exercise testing protocols for HCM patients, aiming to improve treatment monitoring.
Conclusion
The MAPLE-HCM trial marks a significant step forward in HCM care, offering hope for patients who have limited treatment options. As regulatory decisions unfold, the focus will remain on balancing efficacy with safety. For now, the data underscore the importance of personalized, mechanism-based therapies in managing this complex condition.